BioAdaptives (BioAdaptives) EBIT : $-0.57 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is BioAdaptives EBIT?

BioAdaptives's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-0.25 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.57 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioAdaptives's annualized ROC % for the quarter that ended in Mar. 2024 was -14.57%. BioAdaptives's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioAdaptives's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -63.55%.

BioAdaptives EBIT Historical Data

The historical data trend for BioAdaptives's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAdaptives EBIT Chart

BioAdaptives Annual Data

Trend

Dec13

Dec14

Dec15

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-0.04

-0.62

-0.78

-0.61

-0.55

BioAdaptives Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-0.24	-0.09	0.01	-0.23	-0.25

Competitive Comparison of BioAdaptives's EBIT

For the Packaged Foods subindustry, BioAdaptives's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioAdaptives's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioAdaptives's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioAdaptives's EV-to-EBIT falls into.

BioAdaptives EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.57 Mil.

BioAdaptives (OTCPK:BDPT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioAdaptives's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-0.2 * ( 1 - 0% )	/	( (1.322	+	1.424)	/ 2 )
=	-0.2	/	1.373
=	-14.57 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.104	-	0.444	-	( 0.061	-	max(0, 1.751	-	0.089	+	0.061	))
=	1.322

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.059	-	0.451	-	( 0.02	-	max(0, 1.857	-	0.041	+	0.02	))
=	1.424

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

BioAdaptives's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.008	/	( ( (0 + max(-1.394, 0))	+	(0 + max(-1.515, 0)) )	/	2 )
=	-1.008	/	( ( 0	+	0 )	/	2 )
=	-1.008	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.015	+	0.013)	-	(0.444	+	0	+	0.978)
=	-1.394

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.019	+	0.002)	-	(0.451	+	0	+	1.085)
=	-1.515

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BioAdaptives's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-0.565	/	0.889
	=	-63.55 %

BioAdaptives EBIT Related Terms

Thank you for viewing the detailed overview of BioAdaptives's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BioAdaptives (BioAdaptives) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioAdaptives Inc (OTCPK:BDPT) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2620 Regatta Drive, Suite 102, Las Vegas, NV, USA, 89128

Website

https://www.shopbioadaptives.com

BioAdaptives Inc is engaged in investigating, marketing and distributing natural plant- and algal-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. The human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. Its product lines include PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore.

Executives

Richard Chiang	other: Previous Officer and Director	460 BRANNAN STREET SUITE 78064, SAN FRANCISCO CA 94107
Barry Epling	director	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Ferris Holding Inc.	10 percent owner	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Gerald Epling	director, officer: Pres, CEO, Secretary, CFO	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128